| scholarly article | Q13442814 |
| P50 | author | Emily C Williams | Q79205279 |
| P2093 | author name string | Judith I Tsui | |
| Madeline C Frost | |||
| Theresa E Matson | |||
| P2860 | cites work | Epidemiology of hepatitis C virus infection | Q22305500 |
| Impact of alcohol on hepatitis C virus replication and interferon signaling | Q27491301 | ||
| Patient and practitioner characteristics predict brief alcohol intervention in primary care | Q28362506 | ||
| A modified poisson regression approach to prospective studies with binary data | Q29615575 | ||
| The prevalence of hepatitis C virus infection in the United States, 1999 through 2002 | Q29619974 | ||
| Alcohol Use and Human Immunodeficiency Virus (HIV) Infection: Current Knowledge, Implications, and Future Directions | Q30244921 | ||
| Barriers to and facilitators of pharmacotherapy for alcohol use disorder in VA residential treatment programs. | Q30401713 | ||
| An early evaluation of implementation of brief intervention for unhealthy alcohol use in the US Veterans Health Administration | Q30605503 | ||
| Prevalence and correlates of specialty substance use disorder treatment for Department of Veterans Affairs Healthcare System patients with high alcohol consumption | Q34259013 | ||
| BAP updated guidelines: evidence-based guidelines for the pharmacological management of substance abuse, harmful use, addiction and comorbidity: recommendations from BAP. | Q34277168 | ||
| Pharmacotherapy for adults with alcohol use disorders in outpatient settings: a systematic review and meta-analysis | Q34419898 | ||
| Longitudinal predictors of addictions treatment utilization in treatment-naïve adults with alcohol use disorders | Q34424567 | ||
| Alcohol and hepatocellular carcinoma: the effect of lifetime intake and hepatitis virus infections in men and women | Q34520930 | ||
| Barriers to use of pharmacotherapy for addiction disorders and how to overcome them | Q35490468 | ||
| Hepatic safety and antiretroviral effectiveness in HIV-infected patients receiving naltrexone | Q35566908 | ||
| Alcohol and hepatitis C virus--interactions in immune dysfunctions and liver damage | Q35660303 | ||
| Factors associated with first utilization of different types of care for alcohol problems | Q35998920 | ||
| Clinical practice. Unhealthy alcohol use. | Q36036196 | ||
| The Impact of Alcohol Use and Related Disorders on the HIV Continuum of Care: a Systematic Review : Alcohol and the HIV Continuum of Care | Q36275929 | ||
| Extended-Release Naltrexone: A Qualitative Analysis of Barriers to Routine Use | Q36494796 | ||
| Number of Drinks to "Feel a Buzz" by HIV Status and Viral Load in Men | Q36658106 | ||
| Risk of mortality and physiologic injury evident with lower alcohol exposure among HIV infected compared with uninfected men. | Q36689488 | ||
| Substance abuse treatment utilization among adults living with HIV/AIDS and alcohol or drug problems | Q36790638 | ||
| Enhancing access to alcohol use disorder pharmacotherapy and treatment in primary care settings: ADaPT-PC. | Q36886927 | ||
| Utilization of Alcohol Treatment Among HIV-Positive Women with Hazardous Drinking | Q37090964 | ||
| Epidemiology of DSM-5 Drug Use Disorder: Results From the National Epidemiologic Survey on Alcohol and Related Conditions-III. | Q37336196 | ||
| Epidemiology of DSM-5 Alcohol Use Disorder: Results From the National Epidemiologic Survey on Alcohol and Related Conditions III. | Q37589721 | ||
| Chronic hepatitis C virus infection is associated with all-cause and liver-related mortality in a cohort of HIV-infected patients with alcohol problems | Q37625493 | ||
| Dissemination, adoption, and implementation of acamprosate for treating alcohol use disorders | Q37729024 | ||
| Prevalence of clinically recognized alcohol and other substance use disorders among VA outpatients with unhealthy alcohol use identified by routine alcohol screening. | Q38173126 | ||
| Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial. | Q38407349 | ||
| Influence of a targeted performance measure for brief intervention on gender differences in receipt of brief intervention among patients with unhealthy alcohol use in the Veterans Health Administration. | Q38605385 | ||
| Variation in receipt of pharmacotherapy for alcohol use disorders across racial/ethnic groups: A national study in the U.S. Veterans Health Administration. | Q38654314 | ||
| Psychosocial stressors and alcohol use, severity, and treatment receipt across human immunodeficiency virus (HIV) status in a nationally representative sample of US residents. | Q38786168 | ||
| Racial/ethnic differences in initiation of and engagement with addictions treatment among patients with alcohol use disorders in the veterans health administration. | Q39066051 | ||
| Alcohol use and hepatitis C virus treatment outcomes among patients receiving direct antiviral agents | Q39219152 | ||
| Variation in documented care for unhealthy alcohol consumption across race/ethnicity in the Department of Veterans Affairs Healthcare System. | Q39642962 | ||
| Hepatitis C and hospital outcomes in patients admitted with alcohol-related problems | Q39733097 | ||
| Association of Hepatitis C Virus With Alcohol Use Among U.S. Adults: NHANES 2003-2010. | Q39766673 | ||
| Comparative utilization of pharmacotherapy for alcohol use disorder and other psychiatric disorders among U.S. Veterans Health Administration patients with dual diagnoses | Q40569141 | ||
| HIV Care Continuum Applied to the US Department of Veterans Affairs: HIV Virologic Outcomes in an Integrated Health Care System | Q41122022 | ||
| Barriers to hepatitis C treatment in the era of direct-acting anti-viral agents. | Q41930106 | ||
| Impact of hepatitis C virus infection on the risk of death of alcohol-dependent patients | Q42199477 | ||
| Hepatitis C infection and alcohol use: A dangerous mix for the liver and antiviral immunity | Q42999228 | ||
| Pharmacotherapy of alcohol use disorders in the Veterans Health Administration | Q43111681 | ||
| Among patients with unhealthy alcohol use, those with HIV are less likely than those without to receive evidence-based alcohol-related care: A national VA study. | Q43489288 | ||
| Psychiatric disorders and drug use among human immunodeficiency virus-infected adults in the United States | Q43694055 | ||
| Screening for alcoholism in the primary care setting: are we talking to the right people? | Q43942782 | ||
| The prevalence of alcohol consumption and heavy drinking among people with HIV in the United States: results from the HIV Cost and Services Utilization Study | Q44008363 | ||
| Estimating the effect of help-seeking on achieving recovery from alcohol dependence | Q44352258 | ||
| Comorbidity between DSM-IV alcohol and specific drug use disorders in the United States: results from the National Epidemiologic Survey on Alcohol and Related Conditions | Q44634738 | ||
| Pharmacotherapy of alcohol use disorders by the Veterans Health Administration: patterns of receipt and persistence | Q44699433 | ||
| Pharmacotherapy for alcohol dependence: perceived treatment barriers and action strategies among Veterans Health Administration service providers | Q44737385 | ||
| Alcohol-related advice for Veterans Affairs primary care patients: Who gets it? Who gives it? | Q45146245 | ||
| Racial differences in diabetic nephropathy, cardiovascular disease, and mortality in a national population of veterans | Q45333759 | ||
| Influence of alcohol on the progression of hepatitis C virus infection: a meta-analysis | Q45422773 | ||
| Moderate, excessive or heavy alcohol consumption: each is significantly associated with increased mortality in patients with chronic hepatitis C. | Q45731609 | ||
| How important is treatment? One-year outcomes of treated and untreated alcohol-dependent individuals | Q46579900 | ||
| A structured approach to medical management: a psychosocial intervention to support pharmacotherapy in the treatment of alcohol dependence. | Q46751109 | ||
| Assessing and improving organizational readiness to implement substance use disorder treatment in primary care: findings from the SUMMIT study | Q47130417 | ||
| Alcohol-related and mental health care for patients with unhealthy alcohol use and posttraumatic stress disorder in a National Veterans Affairs cohort. | Q47226512 | ||
| Barriers to and Facilitators of Alcohol Use Disorder Pharmacotherapy in Primary Care: A Qualitative Study in Five VA Clinics | Q47633289 | ||
| Addressing unhealthy alcohol use among people living with HIV: recent advances and research directions | Q47695806 | ||
| Increased documented brief alcohol interventions with a performance measure and electronic decision support. | Q49022261 | ||
| Patient factors influencing variation in the use of preventive interventions for alcohol abuse by primary care physicians. | Q51026143 | ||
| Development and verification of a "virtual" cohort using the National VA Health Information System. | Q51937405 | ||
| Receipt of alcohol-related care among patients with HCV and unhealthy alcohol use. | Q54213589 | ||
| General practitioners' promotion of healthy life styles: what patients think | Q71515864 | ||
| Avoiding power loss associated with categorization and ordinal scores in dose-response and trend analysis | Q71716248 | ||
| Disulfiram use in patients with abnormal liver function test results | Q74792541 | ||
| Alcohol treatment utilization: findings from the National Epidemiologic Survey on Alcohol and Related Conditions | Q80139333 | ||
| Alcohol and hepatitis C | Q80530937 | ||
| Hepatic safety of injectable extended-release naltrexone in patients with chronic hepatitis C and HIV infection | Q87409938 | ||
| Level of Alcohol Use Associated with HIV Care Continuum Targets in a National U.S. Sample of Persons Living with HIV Receiving Healthcare | Q89563715 | ||
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | alcohol abuse | Q7331102 |
| P304 | page(s) | 288-295 | |
| P577 | publication date | 2018-10-30 | |
| P1433 | published in | Drug and Alcohol Dependence | Q5308875 |
| P1476 | title | Influence of comorbid drug use disorder on receipt of evidence-based treatment for alcohol use disorder among VA patients with alcohol use disorder and Hepatitis C and/or HIV | |
| P478 | volume | 194 |
Search more.